AssetMark Inc’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.6M Sell
732,448
-25,722
-3% -$673K 0.03% 383
2026
Q1
$21.3M Sell
758,170
-1,755,145
-70% -$46.7M 0.04% 321
2025
Q4
$62.6M Buy
2,513,315
+84,848
+3% +$2.14M 0.13% 135
2025
Q3
$61.9M Buy
2,428,467
+193,859
+9% +$4.78M 0.13% 138
2025
Q2
$54.2M Buy
2,234,608
+195,624
+10% +$4.56M 0.13% 141
2025
Q1
$51.7M Sell
2,038,984
-1,614,128
-44% -$42.2M 0.14% 137
2024
Q4
$96.9M Sell
3,653,112
-46,151
-1% -$1.25M 0.26% 67
2024
Q3
$107M Buy
3,699,263
+103,548
+3% +$3.02M 0.31% 64
2024
Q2
$101M Buy
3,595,715
+124,574
+4% +$3.43M 0.31% 62
2024
Q1
$96.3M Sell
3,471,141
-674,601
-16% -$18.7M 0.31% 69
2023
Q4
$119M Sell
4,145,742
-838,495
-17% -$25.3M 0.43% 50
2023
Q3
$165M Sell
4,984,237
-81,335
-2% -$2.88M 0.66% 36
2023
Q2
$186M Buy
5,065,572
+34,851
+0.7% +$1.36M 0.73% 34
2023
Q1
$205M Buy
5,030,721
+1,110,210
+28% +$48M 0.85% 28
2022
Q4
$201M Buy
3,920,511
+91,217
+2% +$4.37M 0.87% 28
2022
Q3
$168M Buy
3,829,294
+506,338
+15% +$24.6M 0.78% 34
2022
Q2
$174M Buy
3,322,956
+43,643
+1% +$2.22M 0.78% 32
2022
Q1
$170M Buy
3,279,313
+117,967
+4% +$6.12M 0.71% 36
2021
Q4
$187M Buy
3,161,346
+699,270
+28% +$34.6M 0.77% 32
2021
Q3
$106M Sell
2,462,076
-31,926
-1% -$1.41M 0.47% 53
2021
Q2
$97.7M Buy
2,494,002
+34,962
+1% +$1.36M 0.45% 51
2021
Q1
$89.1M Buy
2,459,040
+166,206
+7% +$5.9M 0.46% 53
2020
Q4
$84.4M Buy
2,292,834
+108,880
+5% +$3.99M 0.47% 55
2020
Q3
$76M Buy
2,183,954
+166,031
+8% +$5.82M 0.49% 53
2020
Q2
$64.4M Buy
2,017,923
+435,303
+28% +$14.8M 0.46% 53
2020
Q1
$49M Buy
1,582,620
+1,326,695
+518% +$45.2M 0.42% 64
2019
Q4
$9.51M Buy
255,925
+183,932
+255% +$6.55M 0.07% 202
2019
Q3
$2.45M Buy
71,993
+31
+0% +$1.13K 0.02% 270
2019
Q2
$2.96M Sell
71,962
-797,920
-92% -$31.7M 0.02% 250
2019
Q1
$35.1M Buy
869,882
+141,835
+19% +$5.68M 0.32% 87
2018
Q4
$30.2M Buy
728,047
+679,292
+1,393% +$28.2M 0.29% 83
2018
Q3
$2.04M Sell
48,755
-3
-0% -$115 0.02% 270
2018
Q2
$1.68M Sell
48,758
-2,498
-5% -$85.4K 0.02% 275
2018
Q1
$1.73M Sell
51,256
-27,177
-35% -$934K 0.02% 271
2017
Q4
$2.69M Buy
78,433
+31,937
+69% +$1.09M 0.03% 242
2017
Q3
$1.57M Sell
46,496
-47,871
-51% -$1.54M 0.02% 263
2017
Q2
$3.01M Buy
94,367
+14,187
+18% +$447K 0.04% 222
2017
Q1
$2.6M Buy
80,180
+42,058
+110% +$1.33M 0.03% 229
2016
Q4
$1.17M Sell
38,122
-1,845
-5% -$56.3K 0.02% 254
2016
Q3
$1.28M Buy
39,967
+2,336
+6% +$78.1K 0.02% 241
2016
Q2
$1.26M Buy
37,631
+10,907
+41% +$348K 0.02% 244
2016
Q1
$752K Sell
26,724
-35,955
-57% -$1.03M 0.01% 294
2015
Q4
$1.92M Buy
62,679
+44,900
+253% +$1.41M 0.04% 218
2015
Q3
$530K Sell
17,779
-4,227
-19% -$136K 0.01% 285
2015
Q2
$700K Sell
22,006
-25,543
-54% -$832K 0.01% 344
2015
Q1
$1.57M Sell
47,549
-31,432
-40% -$999K 0.03% 228
2014
Q4
$2.33M Sell
78,981
-4,641
-6% -$133K 0.05% 180
2014
Q3
$2.35M Buy
83,622
+9,298
+13% +$261K 0.05% 169
2014
Q2
$2.09M Buy
74,324
+53,730
+261% +$1.53M 0.04% 195
2014
Q1
$628K Sell
20,594
-665
-3% -$19.8K 0.02% 297
2013
Q4
$618K Sell
21,259
-129,538
-86% -$3.77M 0.01% 310
2013
Q3
$4.11M Buy
+150,797
New +$4.1M 0.1% 112

Other funds holding PFE

AssetMark Inc's PFE Position: Q2 2026 in Review

AssetMark Inc reduced its Pfizer (PFE) stake by 3.4% in Q2 2026, selling an estimated $673K and leaving 732,448 shares worth $17.6M. The position accounts for 0.03% of the portfolio, ranked #383.

AssetMark Inc first reported a position in PFE in Q3 2013 and has held it in 52 quarters since. The position peaked at $205M in Q1 2023. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • AssetMark Inc held 732,448 shares of Pfizer worth $17.6M as of Q2 2026.
  • AssetMark Inc sold 25,722 Pfizer shares in Q2 2026, an estimated $673K.
  • Pfizer made up 0.03% of AssetMark Inc's portfolio in Q2 2026, its #383 holding.
  • AssetMark Inc first reported a position in Pfizer in Q3 2013 and has held it in 52 quarters since.
  • AssetMark Inc's Pfizer position peaked at $205M in Q1 2023.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.